BCL2L1 and leukemia: The combination of apigenin with LY294002 (Figure 5) for treatment of CD34+CD38−/low leukaemia cells, including leukaemia stem cells, induced apoptosis in these cells associated to caspase activation, mitochondrial dysfunction, and downregulation of Bcl-xL and NF-κB [197].